VolitionRX Ltd (VNRX) FinancialsVNRXVolitionRX Ltd

Evaluating the bottom line, VolitionRX Ltd maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1042.50%, while the net margin is -1834.98%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively VNRX converts its operational activities into shareholder value.

In the context of the broader market, VNRX competes directly with industry leaders such as NXL and TRIB. With a market capitalization of $6.48M, it holds a significant position in the sector. When comparing efficiency, VNRX's gross margin of 100.00% stands against NXL's 73.16% and TRIB's 35.21%. Such benchmarking helps identify whether VolitionRX Ltd is trading at a premium or discount relative to its financial performance.

VNRX reported a remarkable 112% year-over-year revenue growth in H1 2026, reaching $1.4 million, but continues to face significant net losses, with a net income of -$7,326,047 in Q2 2026. The gross margin remains strong at 100%, but the net margin is extremely negative, at -1834.98%.